List view / Grid view
12 May 2014 | By Merck
ZONTIVITY added to standard of care demonstrated long-term benefit through three years...
12 May 2014 | By Biogen Idec
Biogen Idec announced that Richard (Rick) A. Rudick, M.D., has joined the company as vice president, Development Sciences, Value-Based Medicine...
12 May 2014 | By AstraZeneca
Study evaluating novel investigational IL-17 receptor antibody meets all primary and secondary endpoints...
12 May 2014 | By Abbott
Early study results suggest Abbott technology equivalent to current standard of care, but produces results much more quickly...
12 May 2014 | By European Pharmaceutical Review
European Drug Target Review is a business-to-business magazine featuring the latest developments in drug discovery and new drug development collaborations...
8 May 2014 | By Boehringer Ingelheim
Details of a new 6,000 patient study of dabigatran etexilate were announced at the European Stroke Conference, Nice, France...
8 May 2014 | By AbbVie
AbbVie submitted marketing authorization applications to the European Medicines Agency seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus infection...
8 May 2014 | By Johnson & Johnson
Filing Includes data from treatment-naïve patients with advanced fibrosis and null responders with all stages of liver fibrosis...
7 May 2014 | By kdm communications
Quotient Clinical has announced the extension of its Translational Pharmaceutics™ platform into patient-focused cancer drug development...
7 May 2014 | By Johnson & Johnson
Demonstrated significant efficacy in manic and depressive mood symptoms and psychosis, and improved patient functioning...
7 May 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced that Brian Daniels, senior vice president, Global Development and Medical Affairs, will be retiring from the company...
7 May 2014 | By Boehringer Ingelheim
Details of a new 6,000 patient study of dabigatran etexilate were announced at the European Stroke Conference...
6 May 2014 | By H. Lundbeck A/S
H. Lundbeck A/S has once again received support and recognition for its research on Parkinson’s disease through a grant from The Michael J. Fox Foundation for Parkinson’s Research...
6 May 2014 | By H. Lundbeck A/S
H. Lundbeck A/S announced that clinical and pre-clinical data highlighting the company’s ongoing commitment to advancing the science and treatment of depression will be presented at the American Psychiatric Association 167th Annual Meeting...
6 May 2014 | By Teva
Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration has approved SYNRIBO® (omacetaxine mepesuccinate) for injection...
